Antibodies News and Research

RSS

Towards a new approach to treating chronic blood disorders

A previously unrecognised weakness in the immune defenses against certain blood neoplasms could offer a promising target for future treatments.

6 Nov 2026

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, USA, December 12–15, 2026.

6 Nov 2026

Anti-PEG antibodies drive contrasting liposome skin toxicity across species

This new article publication from Acta Pharmaceutica Sinica B discusses how anti-polyethylene glycol antibodies affect the movement of stealth liposomes from blood into skin, revealing contrasting distribution and toxicity patterns in mice and rats.

5 Nov 2026

Elusive HIV strains cause breakthrough infections after antibody treatment ends

The broadly neutralizing antibody VRC01 has been thoroughly vetted as a potential prophylactic that could prevent people from becoming infected with HIV.

5 Nov 2026

Three-drug combination remodels immune environment in gastric cancer

A triplet combination therapy can remodel the tumor microenvironment in patients with advanced gastric cancer and shows a promising safety profile, according to results from a new phase 2 clinical trial.

5 Nov 2026

New method detects lung antibodies through non-invasive exhaled breath

For the first time, researchers have succesfully measured antibodies against specific respiratory viruses in exhaled air. This is shown in a new study involving, amongst others, the Karolinska Institutet, published in eBioMedicine.

4 Nov 2026

Researchers uncover how astrovirus spreads without destroying gut cells

Among the various viruses that sicken your gut, some at least leave behind a tiny path of cellular destruction as they replicate, implicating the guilty pathogen.

3 Nov 2026

Engineered beneficial bacteria reduce bloodstream infections after stem cell transplants

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, and collaborators have pioneered a new approach to preventing dangerous bloodstream infections in patients receiving donor stem cell transplants for blood cancers.

3 Nov 2026

Advanced imaging tool improves detection of residual multiple myeloma disease

A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy.

3 Nov 2026

Study identifies new target to improve ulcerative colitis treatments

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease in which persistent mucosal inflammation damages the epithelial barrier.

3 Nov 2026

New hormone receptor strategy offers targeted treatment for lupus

Researchers at the University of California, Riverside and City of Hope have identified a new strategy for treating systemic lupus erythematosus (SLE), or lupus, an autoimmune disease in which the immune system attacks healthy tissues.

2 Nov 2026

Targeting EGFR signaling to reduce mucus overproduction in lung diseases

Airway mucus is part of innate lung defense, but when production overwhelms clearance, it obstructs airflow and worsens disease.

2 Nov 2026

Eating walnuts was linked to higher IgG levels, but what does that mean for health?

A two-year randomized trial involving 474 older adults found that daily consumption of 30–60 grams of walnuts was associated with 6% higher total serum IgG concentrations compared with a control diet, with an 11% difference observed among US participants. Walnut consumption did not significantly affect IgM, MDA-LDL or MDA-LDL-specific antibodies, and whether the modest IgG difference has meaningful cardiovascular benefits remains unknown.

1 Nov 2026

Hyperactive cancer-promoting proteins help tumor cells evade immune attack

The immune system may recognize a cancer cell and still fail to destroy it. Researchers at Hiroshima University and their international collaborators found that hyperactive YAP and TAZ (YAP/TAZ), two cancer-promoting proteins, were associated with genomic instability that may make cancer cells more recognizable to the immune system, while also increasing PD-L2, which helps the cells suppress T-cell attack.

30 Oct 2026